Compare IDEXX Laboratories, Inc. (IDXX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nvidia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Nvidia Corp trades at $229.28 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 137.8× IDEXX Laboratories, Inc.'s market cap, and Nvidia Corp pays a 0.43% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Nvidia Corp for 115 Days on average.
| IDXX | NVDA | |
|---|---|---|
Market Cap | $40.43B | $5.57T |
Volume | 692,164 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $766.68 | $239.27 |
52-Week Low | $504.70 | $165.17 |
Typical Hold Time | 46 Days | 115 Days |
Enterprise Value | $41.32B | $5.54T |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
NVIDIA (NVDA) trades at $230.48, down 2.9% on the day, with strong technical support at $228 and resistance at $235. The company demonstrates exceptional fundamental strength with 2025 revenue of $130.5 billion and net income of $72.9 billion, representing a 55.8% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 forecast.
NVIDIA maintains a dominant position in AI chip markets with accelerating revenue growth projected to reach $303 billion in 2026. While valuation multiples appear elevated (P/E 29.1, P/S 18.6), the consensus price target of $339.17 suggests 47% upside potential. Key risks include increased competition and potential peak AI infrastructure spending, but strong institutional support and positive analyst sentiment (76% buy ratings) support the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
